NICE Update Expands Access to AstraZeneca's Lokelma for Hyperkalaemia Treatment
AstraZeneca's Lokelma, a therapy for high potassium levels in the blood, is set to see wider usage in the NHS following a NICE update. The new guidance lowers the potassium threshold for treatment eligibility from 6.0 mmol/L to 5.5 mmol/L and removes the requirement for specialist initiation. This change is based on real-world evidence showing the drug's effectiveness in managing hyperkalaemia, a condition often associated with chronic kidney disease and heart failure. The update is part of a broader adjustment in NICE's cost-effectiveness threshold, which now ranges from £25,000 to £35,000 per quality adjusted life year. 
